Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

By sjmartinez • September 19, 2023

VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, Kuklinski LF, Collichio F, Sosman JA, Ikeguchi A, Victor AI, Truong TG, Chmielowski B, Portnoy DC, Chen Y, Margolin K, Bane C, Dasanu CA, Johnson DB, Eroglu Z, Chandra S, Medina E, Gonzalez CR, Baselga-Carretero I, Vega-Crespo A, Garcilazo IP, Sharon E, Hu-Lieskovan S, Patel SP, Grossmann KF, Moon J, Wu MC, Ribas A. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med. 2023 Sep;29(9):2278-2285. doi: 10.1038/s41591-023-02498-y. Epub 2023 Aug 17. PMID: 37592104.

Tags: Dermatology, Hematology/Oncology, Publications

Assessing GPT-4’s Diagnostic Accuracy with Darker Skin Tones: Underperformance and Implications

Akuffo-Addo E, Samman L, Munawar L, Akbik M, Kokikian N, Wescott R, Wu JJ. Assessing GPT-4's Diagnostic Accuracy with Darker Skin Tones: Underperformance and Implications.[...]

Engaging industry effectively and ethically in artificial intelligence from the Augmented Artificial Intelligence Committee Standards Workgroup

Lee I, Aninos A, Lester J, Rotemberg V, Schlessinger DI, Weed J, Wongvibulsin S, Daneshjou R. Engaging industry effectively and ethically in artificial intelligence from[...]

A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers

Algazi AP, Moon J, Lao CD, Chmielowski B, Kendra KL, Lewis KD, Gonzalez R, Kim K, Godwin JE, Curti BD, Latkovic-Taber M, Lomeli SH, Gufford[...]